Maredia, Hasina

AbstractObjectivesThere remains an unmet need for a laser‐enabled tissue coring device that can effectively improve face and neck skin laxity and rhytides. We investigate a novel 2910 nm erbium‐doped fluoride glass fiber laser (2910 nm fiber laser) (UltraClear; Acclaro Medical) for laser‐coring of submental tissue.MethodsFive subjects, Glogau scale III−IV, were treated with a single pulse of the laser‐coring mode of the 2910 nm fiber laser in the submentum. A 4 mm punch biopsy was immediately performed. Biopsy specimens were sectioned and stained with hematoxylin and eosin and placed on glass slides. All sections were reviewed, and sections containing the center of the transected core were analyzed for depth and diameter of the ablative microchannel and width of the surrounding zone of coagulation.ResultsA total of 15 intact micro‐cores were analyzed. Histological analysis revealed an average ± standard deviation microchannel diameter of 242.5 ± 65.2 µm, an average ablative depth of 980 ± 318.8 µm, and an average zone of coagulation of 104 ± 32 µm.ConclusionsLaser‐enabled tissue coring with a novel 2910 nm fiber laser can safely achieve a wider microchannel diameter with ablative depth extending to the mid and deep dermis, which has the potential for collagen contraction and tissue tightening. Laser‐coring to this ablation diameter and depth and with the surrounding zone of coagulation was found to be safe without adverse effects of post‐inflammatory erythema or scarring in our study.

AbstractA 2‐year‐old boy presented with an extensive, asymptomatic, photosensitive eruption refractory to topical steroids and tretinoin; examination and biopsies were consistent with generalized linear porokeratosis involving the face, limbs, and trunk. Treatment with topical cholesterol‐lovastatin was initiated, and it successfully improved early erythematous lesions. Whole exome sequencing that targeted mevalonate pathway genes crucial in cholesterol synthesis later revealed a pathogenic, paternally inherited, porokeratosis‐associated MVD, c.70+5 G>A, mutation. Topical cholesterol‐lovastatin is a safe and effective empiric treatment for porokeratosis when used in the early, erythematous phase, and its success is likely mediated through its role in targeting mevalonate pathway mutations.

AbstractObjectiveTo examine the efficacy and safety of a new fractional, ablative erbium:glass fiber (Er:glass) laser (2910 nm) at improving clinical signs of photodamaged skin.Materials and MethodsThirty‐seven healthy participants aged 38–75 years with photodamaged skin were enrolled into two treatment groups. Group A (n = 14) received up to four laser treatments with mild settings, and focal facial subunits were treated with deeper settings. Group B (n = 23) received a single treatment using deeper settings. Following treatment, pain scores and severity and duration of skin responses (erythema, edema, and pinpoint bleeding) were assessed. Primary outcome was the improvement in participant and investigator Global Aesthetic Improvement Scale (GAIS) at 3‐month follow‐up. Secondary outcomes were participant satisfaction with treatment and whether they would repeat treatment.ResultsThirty‐five participants completed the study (n = 1 lost to follow up in each group). Both groups had similar mean participant and investigator GAIS scores of 3/5 corresponding to “Improvement.” All but two patients (both from Group A) reported improvement, satisfaction with treatment, and would repeat treatment. Posttreatment skin responses were mild‐to‐moderate, lasting up to 5 days. There was no scarring or dyspigmentation.ConclusionThe 2910 nm Er:glass laser provided improvement in photoaging with high patient satisfaction.